Longevity science has a reputation problem. Part of the field is serious laboratory work on why tissues deteriorate with age, and part is a marketplace of supplements, clinics and podcasts that borrows the vocabulary without the evidence. Two ideas sit at the center of both: senolytics, drugs meant to clear out aged “zombie” cells, and rapamycin, an old transplant medication that stretches the lives of laboratory mice. This article lays out what each one has actually shown, what remains hypothesis, and why the distance between a long-lived mouse and a healthier person is so large. It is general information, not medical advice.

What is longevity science actually trying to do?

The field is better described as geroscience. Its working premise is that aging itself, the slow accumulation of cellular and molecular damage, is the largest single risk factor for most chronic diseases, including heart disease, many cancers, dementia and type 2 diabetes. If that is right, then slowing the underlying process might delay several diseases at once, rather than fighting them one by one.

That premise is a hypothesis, and a reasonable one, but it is not settled. Nobody has yet shown in a large human trial that a drug can slow aging in general. No regulator currently lists aging as a treatable condition, which is one reason trials tend to target a specific disease, such as bone loss or lung scarring, instead.

The distinction matters when you read headlines. “Extends lifespan in mice” describes an animal result. “Improves a biomarker in people” describes a short human study. “Helps people live longer” describes something no intervention has been proven to do.

What are senescent cells, and why do people want to remove them?

Cells normally divide, repair damage and die on schedule. Under certain stresses, including shortened telomeres, DNA damage and the activation of cancer-promoting genes, a cell can instead enter senescence. It stops dividing but does not die. It stays metabolically active, often grows larger, and carries markers such as p16, a protein used to spot these cells in tissue.

Senescence is not a defect. It is a safeguard. Halting damaged cells helps suppress tumors, and temporary senescence helps wound healing and shapes tissue during embryonic development. The idea that senescent cells are simply “bad” is therefore wrong.

The trouble comes with accumulation. Senescent cells release a mixture of inflammatory signals, growth factors and enzymes known as the senescence-associated secretory phenotype, or SASP. In young tissue the immune system clears the cells fairly quickly. With age, clearance appears to lag, and the cells build up. Their buildup is linked, so far mostly by association and animal work, to frailty, loss of muscle and a range of age-related diseases.

A frequently cited experiment came in 2011, when Darren Baker and colleagues used a genetic trick to eliminate p16-positive cells in mice bred to age prematurely. Removing the cells delayed several age-related disorders. That result, and later ones, gave the field its central pitch: if you can remove the cells without touching healthy tissue, you might blunt some of the damage.

What are senolytics?

Senolytics are small molecules designed to kill senescent cells selectively. Because these cells survive by switching on certain anti-death pathways, drugs that block those pathways can tip them toward self-destruction while leaving normal cells mostly alone.

The best-known candidate is a pairing of dasatinib, a cancer drug, and quercetin, a plant compound found in onions, apples and many supplements. Others include fisetin, another plant flavonoid, and navitoclax, an experimental cancer drug that blocks BCL-2 family proteins. A related class, sometimes called senomorphics, tries to quiet the harmful signaling of senescent cells without killing them; rapamycin and apigenin are sometimes placed there.

Most of the evidence is preclinical. A 2018 mouse study on fisetin reported health and lifespan benefits, and several compounds have cleared senescent cells in animals. Human work is small and early. That does not make it uninteresting, only unfinished.

What have human senolytic trials shown so far?

Two small pilot studies published in 2019 in the journal eBioMedicine gave the first look. One tested dasatinib plus quercetin in people with diabetic kidney disease, and another used the combination in idiopathic pulmonary fibrosis, a scarring lung disease. Both were preliminary and open-label, meaning everyone knew they were receiving treatment, so they can hint at safety and feasibility but cannot prove benefit.

A stronger test arrived in 2024. A Mayo Clinic team published a phase 2 randomized controlled trial in Nature Medicine of intermittent dasatinib plus quercetin in 60 healthy postmenopausal women over 20 weeks, with bone metabolism as the target. The treatment improved a marker of bone formation but did not reduce bone breakdown. The benefit was concentrated in women who began with a high burden of senescent cells, and those women also showed a rise in wrist bone mineral density.

Read that carefully. It is a genuine randomized result, which is rare in this area. It is also one trial, in one population, lasting 20 weeks, using blood markers more than fractures. The senior author, Sundeep Khosla, publicly cautioned against people taking quercetin or fisetin as anti-aging supplements without knowing their senescent cell levels or the correct dose. Three of the authors report financial interests, including patents, related to senolytic drugs, which is common in young fields and worth knowing.

The honest summary: senolytics have shown biological activity in humans in a couple of small studies, and a possible signal in a subgroup. They have not been shown to extend human lifespan or prevent any disease.

What is rapamycin, and why is it central to this field?

Rapamycin, also called sirolimus, was isolated in 1972 from soil bacteria collected on Easter Island, which is where its name comes from. It began life as an antifungal. It was later approved in the United States, in 1999 for a solution and in 2000 for tablets, to help prevent rejection after organ transplants. Further approvals followed for a rare lung disease called lymphangioleiomyomatosis in 2015, a tumor type called malignant PEComa in 2021, and, in a topical form, for facial angiofibromas in 2022.

Its interest for aging comes from what it blocks. Rapamycin inhibits mTOR, a protein complex that acts as a cellular growth controller, tuning how much a cell builds versus how much it recycles. A 2003 study in worms first tied this pathway to aging, and slowing it extended life in yeast, worms and flies as well.

Notice that none of the approvals above is for aging. Using rapamycin to slow aging is off-label experimentation.

Does rapamycin really extend life in mice?

Yes, and this is one of the sturdiest findings in the field. The National Institute on Aging runs the Interventions Testing Program, in which three sites, the University of Michigan, the Jackson Laboratory and the University of Texas Health Science Center at San Antonio, test compounds in genetically diverse mice using a shared design. The studies are powered to detect lifespan changes of 10 to 15 percent, and all results are published, including negative ones.

Rapamycin extended median lifespan in both sexes, even when started late, at 9 or 20 months of age. Females responded more strongly at equivalent doses. Several other compounds also showed effects, including acarbose, aspirin, glycine and 17-alpha-estradiol, though often in only one sex. NIH investigators reported a lifespan extension in 2009, and a 2020 late-life dosing study pointed the same direction, though it found a benefit in males but not females.

That replication across sites is why scientists take it seriously. But mice are not small people. They live about two to three years, they are kept in controlled conditions, and many die of cancer. A drug that suppresses tumors in mice might not offer the same trade in a human with a different disease profile.

What do human rapamycin studies show?

Human data on rapamycin for aging is thin. In 2014, researchers at Novartis reported that everolimus, a close relative, boosted immune responses in older adults when given intermittently. That is a hint of improved immune function, not a longevity result.

The most cited recent trial is called PEARL. Published in April 2025 in the journal Aging, it randomized 114 adults aged 50 to 85 to placebo, 5 mg or 10 mg of compounded rapamycin once a week for 48 weeks. The primary goal was a reduction in visceral fat, the fat around the organs. That goal was not met. The drug was safe and generally well tolerated over the year, with mild gastrointestinal upset the most frequent complaint. Women on 10 mg gained lean muscle and reported less pain, and people on 5 mg reported better emotional well-being and general health on questionnaires.

The authors list limits: a modest sample, a health-conscious group that may have had little room to improve, and compounded rapamycin that appeared to be absorbed less well than commercial versions. Self-reported well-being is also easily influenced by expectation. So PEARL supports short-term safety at low weekly doses and offers some intriguing secondary signals. It does not show that rapamycin slows aging.

What are the risks of taking these drugs?

Rapamycin is an immunosuppressant at standard transplant doses, and the known side effects are not trivial. Mouth ulcers are common, along with diarrhea, nausea, acne and raised cholesterol. Other reported risks include slower wound healing, a higher chance of infection, reduced blood platelets, lung inflammation, kidney effects, and, in transplant patients, higher rates of certain cancers including skin cancer and lymphoma. Inhibiting the second mTOR complex can also impair glucose handling and may raise diabetes risk. Intermittent dosing and related drugs seem to reduce some of these problems in mice, but human dosing for aging is not established.

Senolytics carry their own questions. Dasatinib is a chemotherapy drug whose safety record comes from cancer patients. Quercetin sold as a supplement varies in quality and dose. And because senescent cells serve useful functions in wound healing and tumor suppression, clearing them indiscriminately could in theory cause harm. Intermittent dosing is meant to limit that risk, but long-term human safety data are missing.

Anyone considering either drug should talk to a physician, because the evidence does not currently support self-treatment.

Common questions

Can I buy senolytics or rapamycin to slow my aging?

Rapamycin is a prescription drug, and doctors who prescribe it for longevity are using it off-label without outcome data. Quercetin and fisetin are sold as supplements, but the human trials used specific doses and schedules, often alongside a cancer drug. The trial authors themselves discouraged casual use.

Is there proof that anything extends human lifespan?

Not in the sense of a controlled trial showing longer life from a drug. Lifestyle factors such as not smoking, physical activity and managing blood pressure have strong observational support for reducing disease and early death. No pill has been shown to add years in a randomized human study.

Why do mouse results often fail in people?

Mice differ from humans in lifespan, metabolism, disease patterns and environment. Many treatments that work in mice never reach clinical benefit, and lab mice live in clean conditions that hide risks like infection. Mouse studies are good for generating ideas, not for predicting results in people.

Are zombie cells the main cause of aging?

Scientists do not regard any single process as the sole cause. Senescence is one of several proposed hallmarks of aging, alongside things like DNA damage, altered protein handling and chronic inflammation. How much each contributes in people is still being worked out.

What would a convincing result look like?

A large, long, randomized trial in people showing fewer age-related diseases or better function, replicated by a second group, with clear safety data. Several teams are working toward that, and results will take years.

What to remember

Mouse lifespan extension from rapamycin is well replicated and real. Human evidence for rapamycin and senolytics is early: small trials, short durations, mixed outcomes and mostly biomarkers. Both drugs have side effects that matter, and neither is approved to treat aging. The science is promising enough to deserve serious study and unfinished enough that confident claims, from sellers or skeptics, should be treated carefully.

Further reading

A readable, mainstream overview of the biology of aging research. See it on Amazon (affiliate link)

As an Amazon Associate I earn from qualifying purchases. A commission may be earned if you buy through this link, at no extra cost to you.

Sources